clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Fichtenbaum CJ et al. Reply to 'Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis' by Holmberg and Moorman. 2001 AIDS pmid:11546956
Holmberg SD and Moorman AC Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis. 2001 AIDS pmid:11504998
Johnson RC et al. Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. 2002 AIDS pmid:12172103
Macías J et al. Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection. 1997 AIDS pmid:9030376
Hewitt RG et al. Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease. 1999 AIDS pmid:10449290
Bayoumi AM and Redelmeier DA Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. 1998 AIDS pmid:9727572
Burman WJ et al. Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. 1998 AIDS pmid:9708410
Fichtenbaum CJ et al. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. 2000 AIDS pmid:11153670
High-dose clarithromycin should be avoided. 1996 AIDS Alert pmid:11363723
Physician's aggressive preventive therapy differs. 1995 AIDS Alert pmid:11362774
New drug applications sought. 1995 AIDS Alert pmid:11362777
Researchers find new drugs to fight MAC. 1995 AIDS Alert pmid:11362925
Clarithromycin for MAC. 1995 AIDS Patient Care pmid:11361361
Rosales CM et al. AIDS presenting with cutaneous Kaposi's sarcoma and bacillary angiomatosis in the bone marrow mimicking Kaposi's sarcoma. 2002 AIDS Patient Care STDS pmid:12542930
Mah Ming JB and Gill MJ Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. 2003 AIDS Patient Care STDS pmid:12816614
Monno R et al. Chlamydia trachomatis and Mycobacterium tuberculosis lung infection in an HIV-positive homosexual man. 2001 AIDS Patient Care STDS pmid:11788074
Yangco BG et al. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? 2014 AIDS Patient Care STDS pmid:24833016
Desimone JA et al. Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. 2003 AIDS Patient Care STDS pmid:14746655
NIAID study rules out high-dose clarithromycin for AIDS-related MAC. 1996 AIDS Patient Care STDS pmid:11361534
New data suggest antibiotic clarithromycin is effective in prolonging life of AIDS patients. 1996 AIDS Patient Care STDS pmid:11361575
Clarithromycin and MAC. 1996 AIDS Patient Care STDS pmid:11361673
Different clarithromycin doses affect mortality. 1997 AIDS Patient Care STDS pmid:11361754
Aboulafia DM Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. 2003 AIDS Read pmid:14524324
Kahlon SS et al. Mycobacterium-avium-intracellulare complex immune reconstitution inflammatory syndrome in HIV/AIDS presenting as osteomyelitis. 2008 AIDS Read pmid:18975441
Chu J et al. Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. 2011 AIDS Res Ther pmid:21388558
Smibert OC et al. Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. 2017 AIDS Res. Hum. Retroviruses pmid:28791872
Lai KC et al. Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. 2000 Aliment. Pharmacol. Ther. pmid:10930902
Pilotto A et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. 2000 Aliment. Pharmacol. Ther. pmid:10930903
Gatta L et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. 2005 Aliment. Pharmacol. Ther. pmid:15963079
Spinzi G et al. Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9146769
Peterson WL The role of antisecretory drugs in the treatment of Helicobacter pylori infection. 1997 Aliment. Pharmacol. Ther. pmid:9146787
Masaoka T et al. Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. 2004 Aliment. Pharmacol. Ther. pmid:15298608
Kondo Y et al. Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. 2004 Aliment. Pharmacol. Ther. pmid:15298609
Chiba N et al. Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. 2004 Aliment. Pharmacol. Ther. pmid:14984382
Di Mario F et al. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. 2006 Aliment. Pharmacol. Ther. pmid:16611285
Madisch A et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. 2006 Aliment. Pharmacol. Ther. pmid:16441467
Wong BC et al. One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. 2001 Aliment. Pharmacol. Ther. pmid:11207516
Fakheri H et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. 2001 Aliment. Pharmacol. Ther. pmid:11207517
Peitz U et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. 2002 Aliment. Pharmacol. Ther. pmid:11860415
Sheu BS et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. 2002 Aliment. Pharmacol. Ther. pmid:12197847
Calvet X et al. One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. 2002 Aliment. Pharmacol. Ther. pmid:12144575
Calvet X et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. 2000 Aliment. Pharmacol. Ther. pmid:10792124
John Albert M et al. High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. 2006 Aliment. Pharmacol. Ther. pmid:17059517
Spinzi GC et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. 1998 Aliment. Pharmacol. Ther. pmid:9663722
Malfertheiner P et al. Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. 2003 Aliment. Pharmacol. Ther. pmid:12752349
Gené E et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. 2003 Aliment. Pharmacol. Ther. pmid:12752350
Toracchio S et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. 2000 Aliment. Pharmacol. Ther. pmid:11121913
Pilotto A et al. Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. 1996 Aliment. Pharmacol. Ther. pmid:8971305
Nista EC et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. 2003 Aliment. Pharmacol. Ther. pmid:12969089
Klok RM et al. Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. 2002 Aliment. Pharmacol. Ther. pmid:11966514